SEC Comment Letter for Q (QCLS) — Dec 5, 2019

Q/C TECHNOLOGIES, INC. (QCLS) (CIK 0001321834)
Date: Dec. 5, 2019 · CIK: 0001321834 · Accession: 0000000000-19-016152

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 001-36268

Date

December 5, 2019

Author

Christopher Schreiber

Form

UPLOAD

Company

Q/C TECHNOLOGIES, INC. (QCLS) (CIK 0001321834)

Letter

December 5, 2019 Christopher Schreiber Executive Chairman Akers Biosciences, Inc. 201 Grove Road Thorofare, NJ 08086 Re:Akers Biosciences, Inc. Preliminary Proxy Statement on Schedule 14A Filed November 25, 2019 File No. 001-36268 Dear Mr. Schreiber: We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Sarah Williams, Esq.

Show Raw Text

December 5, 2019
Christopher Schreiber
Executive Chairman
Akers Biosciences, Inc.
201 Grove Road
Thorofare, NJ 08086
Re:Akers Biosciences, Inc.
Preliminary Proxy Statement on Schedule 14A
Filed November 25, 2019
File No. 001-36268
Dear Mr. Schreiber:
            We have completed our review of your filing.  We remind you that the company and its
management are responsible for the accuracy and adequacy of their disclosures, notwithstanding
any review, comments, action or absence of action by the staff.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:       Sarah Williams, Esq.

SecProbe.io